RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Akcijų sąrašas・Lonza Group AG

Lonza Group AG

Uždarymo kaina

SektoriusSveikatos priežiūra

493.4 3.09

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

478.65

Max

494.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	57M 483M
Pardavimai	-621M 3B
P/E Sektoriaus vid.	37.585 67.147
Dividendų pajamingumas	1.04
Pelno marža	16.345
Darbuotojai	20,000
EBITDA	-181M 822M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+37.73% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.04% 2.36%
Kitas uždarbis	2026-07-22

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-4.6B 34B
Ankstesnė atidarymo kaina	490.31
Ankstesnė uždarymo kaina	493.4

Naujienos nuotaikos

By Acuity

14%

86%

24 / 347 reitingas Healthcare

Lonza Group AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-06 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

2026-01-28 06:15; UTC

Uždarbis

Lonza Sales Grow on New Contract Momentum

2025-07-23 08:30; UTC

Uždarbis

Pagrindinės rinkos jėgos

Lonza Shares Rise After Outlook Lift for Core Business

2026-03-09 10:34; UTC

Rinkos pokalbiai

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

2026-03-06 17:12; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

2026-03-06 17:10; UTC

Įsigijimai, susijungimai, perėmimai

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

2026-03-06 17:09; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Retain 40% Stake in CHI

2026-03-06 17:08; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Will Receive Upfront Proceeds of CHF1.7B

2026-03-06 17:07; UTC

Įsigijimai, susijungimai, perėmimai

Lonza: Transaction Expected to Close in 2H

2026-03-06 17:07; UTC

Įsigijimai, susijungimai, perėmimai

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

2026-03-06 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

2026-01-28 12:04; UTC

Rinkos pokalbiai

Uždarbis

Lonza Results Show a Company in Good Shape -- Market Talk

2026-01-28 05:35; UTC

Uždarbis

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

2026-01-28 05:34; UTC

Uždarbis

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

2026-01-28 05:33; UTC

Uždarbis

Lonza Issues 2026 View

2026-01-28 05:32; UTC

Uždarbis

Lonza 2025 Core Ebitda Margin 31.6%

2026-01-28 05:32; UTC

Uždarbis

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

2026-01-28 05:32; UTC

Uždarbis

Lonza 2025 Core Ebitda CHF2.06B

2026-01-28 05:30; UTC

Uždarbis

Analysts Saw Lonza 2025 Sales at CHF7.54B

2026-01-28 05:30; UTC

Uždarbis

Lonza 2025 Sales CHF6.53B

2025-10-27 08:24; UTC

Rinkos pokalbiai

Lonza on Track to Meet Long-Term Goals -- Market Talk

2025-10-23 10:53; UTC

Rinkos pokalbiai

Uždarbis

Lonza Set to Recover as Contracts Flow in -- Market Talk

2025-07-23 08:00; UTC

Rinkos pokalbiai

Uždarbis

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

2025-07-23 04:44; UTC

Uždarbis

Lonza 1H Sales Grew 19% at Constant Currency

2025-07-23 04:43; UTC

Uždarbis

Lonza 1H Core Ebitda Margin 29.6%

2025-07-23 04:43; UTC

Uždarbis

Lonza: Margins Will Be Only Minimally Affected

2025-07-23 04:42; UTC

Uždarbis

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

2025-07-23 04:42; UTC

Uždarbis

Lonza: This Is Mainly From Weakening of U.S. Dollar

2025-07-23 04:38; UTC

Uždarbis

Lonza 1H Net Pft CHF426M

2025-07-23 04:37; UTC

Uždarbis

Lonza Backs 2025 View for CHI Business

Akcijų palyginimas

Kainos pokytis

Lonza Group AG Prognozė

Kainos tikslas

By TipRanks

37.73% į viršų

12 mėnesių prognozė

Vidutinis 660 CHF 37.73%

Aukščiausias 670 CHF

Žemiausias 630 CHF

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Lonza Group AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Lonza Group AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

24 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.